Arcellx, Inc. (ACLX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Redwood City, MD, United States. Der aktuelle CEO ist Rami Elghandour.
ACLX hat IPO-Datum 2022-02-04, 163 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $6.72B.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for patients with cancer and other serious diseases. The company's lead candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, while its pipeline includes ACLX-001, a dual-targeting immunotherapy combining ARC-T cells and SparX proteins, as well as additional programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Founded in 2014 and headquartered in Gaithersburg, Maryland, Arcellx focuses on advancing next-generation cell and protein-based therapies to address unmet medical needs in oncology.
